CarsonAllaria Wealth Management’s Charles River Laboratories CRL Stock Holding History

CarsonAllaria Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-71	Closed	-$10.8K	–	134
2025 Q2	$10.8K	Hold	71	–	–	0.01%	248
2025 Q1	$10.7K	Hold	71	–	–	0.01%	247
2024 Q4	$13.1K	Hold	71	–	–	0.01%	228
2024 Q3	$14K	Hold	71	–	–	0.01%	233
2024 Q2	$14.7K	Hold	71	–	–	0.01%	219
2024 Q1	$19.2K	Hold	71	–	–	0.01%	192
2023 Q4	$16.8K	Hold	71	–	–	0.01%	184
2023 Q3	$13.9K	Hold	71	–	–	0.01%	185
2023 Q2	$14.9K	Hold	71	–	–	0.01%	191
2023 Q1	$14.3K	Hold	71	–	–	0.01%	187
2022 Q4	$15K	Hold	71	–	–	0.01%	167
2022 Q3	$14K	Hold	71	–	–	0.01%	167
2022 Q2	$15K	Hold	71	–	–	0.01%	160
2022 Q1	$20K	Hold	71	–	–	0.02%	162
2021 Q4	$27K	Buy	+71	New	+$27.6K	0.02%	157

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CarsonAllaria Wealth Management's CRL Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 71 shares — an estimated $10.8K sold.

CarsonAllaria Wealth Management first reported a position in CRL in Q4 2021 and held it in 15 quarters. The position peaked at $27K in Q4 2021. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

CarsonAllaria Wealth Management reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 71 Charles River Laboratories shares in Q3 2025, an estimated $10.8K.
CarsonAllaria Wealth Management first reported a position in Charles River Laboratories in Q4 2021 and held it in 15 quarters.
CarsonAllaria Wealth Management's Charles River Laboratories position peaked at $27K in Q4 2021.
556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.